NCT07445022 is a Phase 4 clinical trial of tunlametinib in Melanoma Advanced, sponsored by Fudan University.

Who is sponsoring NCT07445022?

NCT07445022 is sponsored by Fudan University.

What drugs are being tested in NCT07445022?

Interventions in NCT07445022: tunlametinib.

What condition does NCT07445022 study?

NCT07445022 studies Melanoma Advanced.

Is NCT07445022 still recruiting?

NCT07445022 is currently recruiting now. Last updated 3 March 2026.

Last reviewed 2026-03-03 · How we verify

NCT07445022

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

Recruiting now Phase 4 Last updated 3 March 2026

What this trial tests

Phase 4 trial testing tunlametinib in Melanoma Advanced in 110 participants. Currently enrolling.

Timeline

28 January 2026

Primary endpoint
30 September 2028

31 January 2029

Quick facts

Lead sponsor	Fudan University
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	110
Start date	28 January 2026
Primary completion	30 September 2028
Estimated completion	31 January 2029
Sites	1 location across China

Drugs / interventions tested

tunlametinib — full drug profile →

Conditions studied

Melanoma Advanced — all drugs for Melanoma Advanced →

Sponsor

Fudan University

Who can join

18 and older, any sex, with Melanoma Advanced. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of tunlametinib

Trials testing the same drug.

NCT06008106 — Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma · Phase 3 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07445022 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 3 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07445022.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing